The severity of Parkinson's is measured on a scale of 5 stages. Read on to learn more about the disease and its progression.

TUCSON, Ariz., March 10, 2026– Critical Path Institute® (C-Path) applauds the publication of a new study in the Journal of Neurology that offers critical longitudinal insights into how symptoms and ...

Parkinson’s disease (PD) is a complex, progressive neurological disorder characterized by a range of motor and non-motor symptoms. The most commonly used assessment in PD is the Movement Disorder ...

A diabetes drug called lixisenatide has produced the first strong clinical evidence that a small molecule can slow the actual progression of Parkinson’s disease, not simply mask its symptoms. In a ...

Reliable progression models are essential for clinical decision-making and trial design in Parkinson’s disease. We discuss linear, exponential, and sigmoidal patterns in PET and SPECT data, ...

About 90,000 Americans are expected to be diagnosed with Parkinson’s disease this year. Researchers say early deep brain stimulation and new therapies may help slow progression. TULSA, Okla. - About ...

Scientists have identified a protective brain pathway that may help slow the progression of Parkinson's disease by strengthening the brain's own dopamine‑producing neurons, but the positive effect was ...

PHILADELPHIA—Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson’s disease (PD). This protein, called glycoprotein nonmetastatic ...

This symposium reviewed the evolving understanding of the molecular pathophysiology and disease heterogeneity across Alzheimer's disease (AD) and Parkinson's disease (PD). Explored current and ...